About Adcendo

Adcendo ApS is a clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.

The company is developing a pipeline of first- and potential best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies.

Adcendo is currently advancing three ADCs in the clinic:

1. 1) ADCE-T02 targeting Tissue Factor, which is overexpressed in a broad range of solid tumors, including head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer;
2. 2) ADCE-D01 targeting uPARAP, which is overexpressed in high unmet need cancers, including soft tissue sarcoma and other cancers of mesenchymal origin; and
3. 3) ADCE-B05, for which the target is undisclosed, is currently being evaluated in squamous cell tumors.

For further information, please visit https://adcendo.com  or follow us on LinkedIn.